Background: Costs for large animal studies have escalated. Therefore there is a need to develop small animal models of non-ischemic cardiac failure and accurate non-invasive techniques that will allow serial quantitation of left ventricular function. Objectives: The purpose of our study was to determine the efficacy and reliability of adriamycin for inducing cardiomyopathy in rats. We hypothesized that high frequency transthoracic 2-dimensional and M-mode echocardiography would allow for serial testing of cardiac function in this small animal model. Methods: Adriamycin was administered at a dose of 2.5 mg / kg intravenously once a week for 10 weeks in 54 rats. Transthoracic echocardiography by use of a 7.5 MHz transducer was performed in 19 rats at baseline and additionally at 12 weeks after beginning of adriamycin therapy to measure left ventricular dimensions and calculate fractional shortening. Results: The mortality rate during the treatment period was 11%, but increased to 52% at 13 weeks. Transthoracic echocardiography provided adequate visualization of left ventricular dimensions and cardiac function in a parasternal short axis view. In follow-up echocardiography, pericardial effusion was detected in 8 / 19 rats (42%). Compared to baseline, end-diastolic diameters increased from 0.5660.06 to 0.6460.08 mm ( p,0.001), end-systolic diameters increased from 0.2760.03 to 0.4260.08 mm ( p,0.001), and fractional shortening decreased from 52.864.0 to 34.367.1% ( p,0.001) at 12 weeks. Electron microscopy in a subset of rats revealed cardiomyocyte degeneration, mitochondrial and sarcoplasmatic reticular edema, numerous intracellular vacuoles and 'onion-ring' shaped mitochondrial cristae, characteristic for adriamycin cardiotoxicity in human patients. Conclusion: Adriamycin at an intravenous dose of 2.5 mg / kg over 10 weeks can be used to create a reliable model of non-ischemic dilated cardiomyopathy with a high success rate. For in-vivo diagnostic purposes, transthoracic echocardiography provides a reliable technique to non-invasively assess cardiac function quantitatively and qualitatively in follow-up studies in rat cardiomyopathy. This small animal model can easily be used for testing new therapeutic strategies in cardiac failure.
Introduction
myocardium. To study the effects of new drugs or therapeutic concepts several animal models for congestive heart Chronic heart failure in man, which can be caused by failure are available, i.e. cardiac failure caused by exischemic or non-ischemic cardiomyopathy, remains a perimental volume and pressure overload, myocardial major cause of morbidity and mortality. Chronic animal ischemia or infarction, rapid pacing, or drug-induced models are needed to mimic the pathophysiological concardiomyopathies [1] . It is, however, difficult to perform dition of heart failure including severely impaired hemosurvival studies in heart failure models using large animals dynamic function, clinical signs of heart failure, and because of increasing costs. Based on financial restraints, cellular, subcellular, and metabolic alterations in the technical equipment needs, skills and availability, small animal models such as rats or mice represent the future targets in cardiovascular research, including use of trans-exist, imaging techniques that can be used to assess left 2.2. Echocardiography ventricular function in these small animals with cardiomyopathy, have not been widely established, yet.
For echocardiographic studies, inhalative anesthesia was Adriamycin, an anthracycline antibiotic and antineoplasinduced and maintained by the use of methoxyflurane tic agent, is used in chemotherapy for the treatment of (closed container technique). The chest was shaved, and several cancers in humans. One well known side-effect of the animals were positioned on their left side. A 7.5 MHz prolonged therapy is the development of congestive heart commercially available standard pediatric transducer which failure due to a proposed calcium overload and its direct used phased array technology for beam formation (64 cardiotoxicity. It is hypothesized that lipid peroxidation elements) and a lateral and axial resolution between 0.2 and generation of oxygen-derived free radicals [2, 3] disand 0.5 mm was connected to a echocardiographic comrupt cellular membranes finally leading to degenerative puter console (Hewlett Packard 1500, Andover, MA). The dilated cardiomyopathy, which is relatively refractory to interrogation depth was set at 4 cm. conventional treatment strategies [4] [5] [6] [7] .
A parasternal long axis view was followed by a parasterIn human patients, echocardiography is used as a nonnal short axis view. Left ventricular end-systolic and endinvasive diagnostic technique to visualize morphologic or diastolic diameters were measured at the level of the functional changes in adriamycin-induced cardiomyopathy papillary muscles using two-dimensional guided M-mode [8] [9] [10] . Models using adriamycin-induced cardiomyopathy imaging. Fractional shortening was calculated. Measurehave mainly been reported in rabbits [11] [12] [13] , but also in ments of left ventricular dimensions were performed ondogs [14] , mice [15] , and rats [16] . To our knowledge, line from the screen and repeated later. To avoid intrainfunctional non-invasive follow-up studies in the rat model dividual variations due to potential failures of measurehave not been described, yet. Therefore, the purpose of our ments caused by difficulties in detection of endocardial study was to (1) determine whether a reliable small animal border zones in some cases and to ensure reproducibility of model of dilated cardiomyopathy could be developed in the measurements beat-to-beat and intraobserver variability the rat and (2) to evaluate whether transthoracic echwere analyzed. For all rat hearts, between three and six ocardiography represents a reliable technique to image the beats were measured using the same transducer position heart in this small animal model. and angle in the same stop image frame. The mean values of all measurements were used for further analysis. All measurements were conducted by the same investigator 2. Methods (E.R.S.), but were reviewed by two other investigators (C.P. and R.A.K.), who had experience in echocardiog-A total of sixty female Sprague-Dawley rats, weighing raphic analysis of rodent hearts [17, 18] . The intra-and between 164 and 253 g were used. Fifty-four rats were interobserver variability, which has been described before used for later treatment with adriamycin. Histologic analyfrom our group [19] , was analyzed in a subgroup of 10 rat sis including electron microscopy of the left ventricle was hearts for intra-and 30 rat hearts for inter-observer performed in a subset of five adriamycin-treated rats. All variability. For measurements of left ventricular dimenexperiments were conducted in accordance with the institusions, the recommendations of the American Society of tional guidelines for use and care of laboratory animals Echocardiography were used [20] . The total examination which conforms with the Guide for the Care and Use of time was less than 10 min; thereafter rats were allowed to Laboratory Animals published by the US National Instirecover. tutes of Health (NIH Publication No. 85-23, revised 1985).
A model of dilated cardiomyopathy

Results
Fifty-four rats received 2.5 mg / kg adriamycin as an 3.1. Follow-up intravenous tail vein infusion once a week for a total of 10 weeks. Six rats served as controls and received the same None of the control rats -which were healthy and only amount of saline as an intravenous tail vein infusion once a treated with saline -died during the 10-week saline week for a total of 10 weeks. For the intravenous injection, injection period. One rat in the treated group died during the rats were restrained. Transthoracic echocardiography the first injection of adriamycin; additionally two rats died was performed in all rats at baseline and a subgroup of 22 within the first week. Three rats died during the ninth and rats was chosen for follow-up echocardiography (19 tenth week of therapy, presumably due to severe cardiac adriamycin-treated rats and 3 controls) after 12 weeks (2 failure. Therefore, the total mortality rate at follow-up (10 weeks after cessation of adriamycin treatment). To comweeks after start of the 10-week adriamycin therapy) was pare baseline and post-treatment echocardiography in the 11%. However, after completion of the adriamycin treatadriamycin-treated group, data from these 19 rats were ment period, cumulative mortality was 37% within the used for further analysis.
following 2 weeks (total of 12 weeks) and increased to parasternal site, which enabled a short axis view. The circumference of the left ventricle in its middle portion and at the level of the mitral valve could clearly be detected. Epicardial and endocardial borders could be visualized. However, in some animals, the anterior wall and the interventricular septum could not clearly be distinguished in a short axis view. In these animals, a parasternal long axis view and substernal four chamber view were performed additionally to measure left ventricular dimensions. Left ventricular diameters were 0.5660.06 cm at enddiastole and 0.2760.03 cm at end-systole. Fractional shortening was 52.864.0% (Table 1) . Follow-up echocardiography in three control rats with saline injections for 10 weeks revealed no reduction in fractional shortening if compared to baseline echocardiography. In the 19 rats subjected to adriamycin therapy and follow-up echocardiography, baseline echocardiographic 74% within 4 weeks (total of 14 weeks), presumably dimensions were not different compared to the control caused by severe congestive heart failure. The follow-up population. Physical examination at 10 weeks revealed mortality during and after the treatment period is shown in ascites in 13 animals (68%) but in none of the control rats. Fig. 1 .
Initially, body weight increased in the adriamycin-treated animals (from 225.9612.9 g to 242.6629.8 g at 10 weeks, 3.2. Transthoracic echocardiography p,0.05), but then decreased by 12 weeks (to 228.9630.5 g, not significant versus baseline), presumably due to To analyze beat-to-beat variability the highest and the worsening of the clinical condition. In contrast, body lowest of the three to six measurements were taken. The weight in the six control rats increased from 186.0611.3 g beat-to-beat correlation coefficient for the absolute endto 335.0620.0 g at 12 weeks (2 weeks after cessation of diastolic diameter was r50.91 with a standard error of the saline injection, p,0.001 versus baseline and versus the estimate (SEE) of 0.04 cm and r50.98 (SEE50.018) for adriamycin-treated rats). Follow-up echocardiography the absolute end-systolic diameter. Intraobserver variability showed pericardial effusions in eight adriamycin-treated was measured by analyzing the heart beats in the same animals (42%), and increased left ventricular dimensions. echocardiographic image frames at two separate occasions
In control rats, no pericardial effusions were detectable. in 10 randomly selected hearts. The correlation for end-
The methods and duration of anesthesia using methoxyfludiastolic diameters was r50.973 (SEE50.013) and for rane were identical for both the baseline and the follow-up end-systolic diameters r50.975 (SEE50.009). Interobechocardiographic examinations. At follow-up, fractional server variability between two investigators was analyzed shortening was reduced in all adriamycin-treated rats in 30 measurements and revealed a correlation of r50.956 (Table 1 and Figs. 2-6) but not in controls. (SEE50.044) for end-systolic and end-diastolic diameters.
In 5 / 19 rats, end-diastolic diameters did not increase, but end-systolic diameter did and thus, fractional short-3.2.1. Baseline echocardiography ening was reduced. Two of these rats died between the At baseline, the left ventricle was well visualized in all 13th and 14th week after start of adriamycin treatment.
rats and measurements of left ventricular dimensions
The three others survived the observation period, but died were performed. The transducer was positioned on the left at the 17th week. 
Electron microscopy
Electron microscopic analysis was performed in five adriamycin-treated rats and revealed partially degenerated cells, numerous intracellular vacuoles, swollen mitochondria with 'onion ring' shaped cristae, and swollen sarcoplasmatic reticulum (Figs. 7-9) . Two of these hearts were among those in which end-diastolic diameters did not increase at echocardiographic follow-up. The histologic pattern of adriamycin-induced cardiotoxicity was similar to those with enlarged end-diastolic diameters (Fig. 9 ). reliably caused dilated cardiomyopathy in the rat model resulting in severe heart failure; (2) electron microscopic analysis demonstrated cellular degeneration and ultrastructural changes including myocyte vacuolation and interstitial edema, characteristic for adriamycin-induced cardiotoxicity [4, 6, 16] ; (3) transthoracic echocardiography represents a useful technique for imaging the development of dilated cardiomyopathy in this small animal model with accurate assessment of left ventricular dimensions with a low variability of measurements, and demonstrated a significant increase in end-diastolic and end-systolic diameters, and a decrease in fractional shortening.
Discussion
Adriamycin-induced cardiomyopathy in the rat
Adriamycin-induced cardiomyopathy has been described before in the rat model [16, 21] . However, the definite dosage of adriamycin, i.e. from 1 mg / kg body weight to intraperitonealy or intravenously, and the total duration of treatment, i.e. from 6 to 20 weeks, varied. Using our techniques, i.e. 2.5 mg / kg adriamycin, administered intravenously once a week for 10 weeks, all animals developed cardiac failure. This was shown by the clinical condition of the animals including a high incidence of ascites, initial increase but later decrease of body weight after the 10-week treatment period, and echocardiographic evidence of reduced global cardiac function. Moreover, in contrast to Wakasugi et al., who found a mortality rate of 82% within the treatment period in rats treated with 2 mg / kg adriamycin, administered subcutaneously for 10 weeks [21] , our mortality rate during the treatment period was less than 12% (only three rats died during the first week and three treated rats died in the ninth or tenth week), although it increased thereafter. The reason for this difference is not clear, but the subcutaneous route of adriamycin administration might have caused severe local and systemic infections, which may contribute to the high Fig. 5 . Short axis view of the left ventricle of a rat at baseline (upper panels) and 2 weeks after completion of a 10-week adriamycin treatment period (lower panels). To the left, the left ventricle is shown at end-diastole, to the right, the left ventricle is shown at end-systole. At baseline, the changes of the left ventricular dimensions are easily detectable. In contrast, adriamycin-induced cardiomyopathy shows almost no difference in left ventricular dimensions between systole and diastole with very low fractional shortening (LV5left ventricular cavity, ed5end-diastole, es5end-systole). mortality rate in the study of Wakasugi et al. We prefer the contrast to the rabbit models of adriamycin-induced carintravenous application, which was done by briefly rediomyopathy, all the rats with follow-up echocardiography straining the animals without anesthesia. Furthermore, in in our study demonstrated severely reduced fractional Fig. 6 . M-mode echocardiographic images of a rat heart at baseline (upper panel) and at 2 weeks after completion of a 10-week adriamycin treatment period (lower panel). In adriamycin-induced cardiomyopathy, there is global left ventricular hypokinesis and an enlarged left ventricular cavity (end-systolic diameter 0.322 cm, end-diastolic diameter 0.525 cm), compared to the same heart at baseline (end-systolic diameter 0.203 cm, end-diastolic diameter 0.458 cm). Calculated fractional shortening is 56% at baseline and 39% after adriamycin-induced cardiomyopathy had been developed (LV5left ventricular cavity, SEPT5septal wall, PW5posterior wall). shortening (Fig. 4) . In contrast, in the rabbit model Pye et 4.2. Transthoracic echocardiography al. found a reduction in ejection fraction only in 7 / 16 animals, indicating 56% of unsuccessfully treated animals Qualitative and mainly quantitative 2-dimensional ech- [22] . Therefore, the model described here using the rat ocardiography provides in vivo dynamic assessment of represents a cost-effective, reproducible and accurate ventricular function, cardiac motion and mechanical abnormodel with a high incidence of cardiomyopathy and a low malities in human patients as well as in experimental mortality during the treatment phase but increased mortalianimals. In research studies, echocardiography is used in ty due to severe cardiac failure during the observation different species up to the size of the transducer itself, i.e. period of 4 weeks thereafter.
in mice we recently demonstrated that 2-D echocardiog- raphy provides accurate estimation of left ventricular represent a promising non-invasive, cost-effective diagnosdimensions and function [17] . In the rat heart, 2-D tic tool which reliably can be performed to study different echocardiography is an established procedure for assesstreatment strategies. ment of ventricular geometry, global left ventricular function, stroke volume, and cardiac index in normal, hypertrophied, congenitally malformed, and ischemic or 4.3. Histological findings necrotic myocardium [23] [24] [25] [26] [27] [28] [29] . However, most of these studies had no follow-up and non-ischemic rat models of As previously reported by use of a histological scoring cardiomyopathy are rare. Since echocardiography is fresystem in rabbits, a negative correlation was found bequently used in human patients treated with adriamycin for tween ejection fraction and the amount of myocardial detection of functional changes [6, [8] [9] [10] 30] , there is need degeneration [22] . Since the findings of cellular degenerafor an adequate comparable animal model. tion, swollen mitochondria and vacuolation were typical Evaluation of cardiac function by echocardiography in for severe adriamycin cardiotoxicity in human patients dogs with adriamycin-induced cardiomyopathy has been [4] [5] [6] [7] , our findings indicate that the functional changes reported recently [14] , demonstrating gradually reduced detected by echocardiography are caused by adriamycin fractional shortening over an observation period of 21 cardiotoxicity. Thus, in addition to the availability of a weeks. In this study, however, no increase in left ventricumodel of non-ischemic cardiomyopathy and a diagnostic lar dimensions has been shown. This is in contrast to our non-invasive technique for follow-up studies, this rat findings in the rat model, since we found a significant model may be used to study (1) the cellular and metabolic increase of end-systolic as well as end-diastolic diameters, effects of adriamycin cardiotoxicity which are similar to which easily could be visualized by two-dimensional and findings in human patients, and (2) the avoidance of these M-mode echocardiography at 12 weeks. In rabbits, transmorphologic and functional alterations by use of different thoracic echocardiography revealed a reduction in ejection protective treatment strategies. fraction and an increase in diastolic left ventricular dimenOne limitation of this study is the absence of invasively sions at 20 weeks after start of an 8-week adriamycin evaluated hemodynamic data. However, invasive surgical treatment period, compared to control animals [22] . In this procedures may limit a follow-up and survival studies and study, however, no intra-individual follow-up echocardiogmight even alter the hemodynamic condition (i.e. a chroniraphy had been performed.
cally occluded carotid artery after invasively measured To our knowledge, we present the first study demonblood pressure) in rats. On the other hand, alterations of strating the feasibility of follow-up echocardiography to hemodynamics including cardiac output in adriamycindetect a change in left ventricular dimensions and a treated rats have been reported before [31] [32] [33] [34] . Therefore, reduction of contractile cardiac function in adriamycininclusion of invasive hemodynamic measurements was not induced cardiomyopathy in rats. This technique might part of our study design. It is also unlikely that humans
